Vaccine News and Research

Latest Vaccine News and Research

Enrollment complete in Nabi's first NicVAX Phase III clinical trial for nicotine addiction

Nabi Biopharmaceuticals announced today that it has completed enrollment in the first Phase III clinical trial of NicVAX® (Nicotine Conjugate Vaccine), the company's innovative and proprietary investigational vaccine being developed to treat nicotine addiction and prevent smoking relapse.

15 Jul 2010

Amorfix grants Biogen Idec exclusive worldwide rights to lead ALS monoclonal antibodies

Amorfix Life Sciences Ltd. today announced that it has entered into a licensing agreement granting Biogen Idec exclusive worldwide rights to Amorfix's lead amyotrophic lateral sclerosis (ALS) monoclonal antibodies. The antibodies have shown efficacy in animal models of ALS and Biogen Idec will now, at its expense, complete the development and prepare for clinical trials.

15 Jul 2010

Hendra virus treatment to be ready in a few months

Of the dozen people who were exposed to a horse infected with the Hendra virus, 11 have been cleared of the infection by repeated tests on Queensland's Sunshine Coast. These 12 people had first come into contact with the infected horse at Tewantin in May and have since then been subjected to testing to rule out infection with the deadly virus. It is expected that the 12th person will also be cleared soon. Quarantine restrictions were also lifted last month.

14 Jul 2010

NIAID awards ATCC multimillion dollar MID-BRR contract

ATCC, the premier biological materials resource, services, and standards organization, has been awarded the National Institute of Allergy and Infectious Diseases, Microbiology and Infectious Diseases Biological Resource Repository ("MID-BRR") contract, ATCC announced today. The current value of the contract is $14,615,598 with the ultimate value of $115,733,409 over 7 years with an annual renewal.

14 Jul 2010

Media outlets focus on audiences towards Alzheimer's disease: Intellect Neurosciences

Intellect Neurosciences, Inc., a biopharmaceutical company engaged in the discovery and development of disease-modifying therapeutic agents for the treatment and prevention of Alzheimer's disease, today announced that it is pleased with the recent press coverage the Company and Dr. Daniel G. Chain, Ph.D., the Company's Chairman and Chief Executive Officer, recently has received.

14 Jul 2010

Health Canada approves FluMist for preventing seasonal influenza

AstraZeneca Canada Inc. announced today that Health Canada has approved FluMist (Influenza Vaccine, Live, Attenuated) for the prevention of seasonal influenza. FluMist is the first vaccine in Canada that is administered as a gentle mist sprayed into the nose.

14 Jul 2010

Scientists discover three human antibodies that neutralize HIV

Scientists have discovered three previously unknown human antibodies that neutralize HIV, two of which target a broad range of HIV strains. The findings, reported online July 8 in two Science papers, add a level of encouragement to the AIDS vaccine research field.

14 Jul 2010

IAS announces recipients of CNIHR grants

The International AIDS Society today announced the recipients of its first joint research grant programme, Creative and Novel Ideas in HIV Research. CNIHR grants, funded in partnership with the U.S. National Institutes of Health and the NIH-supported Centers for AIDS Research are designed to promote innovative research and new ideas from early stage investigators whose primary focus has previously been in fields of scientific inquiry other than HIV/ AIDS.

14 Jul 2010

New research studies presented at Alzheimer's Association International Conference

The primary therapeutic target in Alzheimer's disease has been the beta amyloid peptide, which clusters outside cells in the brain to form sticky clumps known as plaques. Recently, more attention has been given to the tau protein, which aggregates inside the brain cells of people with Alzheimer's, forming neurofibrillary tangles. Precisely how these proteins interact in causing the disease is unclear.

14 Jul 2010

Emergent awarded $107M HHS BARDA contract to develop large-scale manufacturing of BioThrax

Emergent BioSolutions Inc. announced today that it has signed a contract valued at up to $107 million with the Office of the Biomedical Advanced Research and Development Authority (BARDA) of the Department of Health and Human Services (HHS), to develop and obtain regulatory approval for large-scale manufacturing of BioThrax® (Anthrax Vaccine Adsorbed) in Building 55. Building 55 is the company's large-scale state-of-the-art vaccine manufacturing facility in Lansing, Michigan.

14 Jul 2010

LSUHSC Professor awarded $2.1M grant to determine role of PCP

Dr. Jay Kolls, Professor and Chairman of Genetics at the LSU Health Sciences Center New Orleans School of Medicine, has been awarded a $2.1 million grant over five years by the National Heart, Lung, and Blood Institute of the National Institutes of Health to determine the role and identify which T-helper cells fight the opportunistic infection, Pneumocystis carinii pneumonia, which can be a complication of HIV/AIDS.

14 Jul 2010

Administration to unveil first national HIV/AIDS strategy today

The White House will unveil the first formal national HIV/AIDS strategy on Tuesday, a plan that aims to reduce the number of new cases by 25 percent in the next five years, officials said. Noting that the number of new infections in the United States has been static -- and that the number of people living with HIV is growing -- the new policy would direct more resources toward African Americans and gay and bisexual men. Latinos and substance abusers should also be a priority, the report says.

14 Jul 2010

Antigen Express granted patent for AE37 immunotherapeutic vaccine: Generex Biotechnology

Generex Biotechnology Corporation today announced that its wholly-owned subsidiary, Antigen Express, Inc., has been granted a United States patent on AE37, its lead immunotherapeutic vaccine. While Antigen Express has a strong intellectual property foundation on all Ii-Key technology, this is the first "composition of matter" patent to be issued relating to one of their development products.

14 Jul 2010

Opinions: Haitian rebuilding; Nuclear state vaccine initiatives; HIV rights abuses in China; HIV vaccine

The "paltry scale of the Pentagon's reconstruction endeavor [in Haiti] -- 1.6 million people displaced and the American military is contributing a few classrooms? -- is emblematic of the international response," columnist Dana Milbank writes in a Washington Post opinion piece.

14 Jul 2010

Anti vaccine group has only a week left to heed to HCCC’s warnings

The New South Wales Health Care Complaints Commission disapproves of the anti vaccination reports from a Bangalow, NSW based Australian Vaccination Network.

13 Jul 2010

Emergent BioSolutions hosts forum to raise global awareness of the importance of biopreparedness

Emergent BioSolutions Inc. is hosting "Bioterrorism Prevention, Preparedness and Response," a forum organized for members of the North Atlantic Treaty Organization Parliamentary Assembly to raise global awareness of the importance of biopreparedness.

13 Jul 2010

Clinical trial initiated to evaluate LibiGel on cognitive function in menopausal women

BioSante Pharmaceuticals, Inc. today announced the initiation of a LibiGel (testosterone gel) clinical trial to evaluate its effect on cognitive function in menopausal women. The trial is a randomized, 6-month comparison of the effect of LibiGel compared to placebo treatment on a variety of learning and memory tasks. The study is being conducted by Dr. Susan Davis, Professor of Women's Health, Department of Medicine, Monash University Women's Health Program in Australia.

13 Jul 2010

NIAID names Case Western Reserve University as International Center of Excellence for Malaria Research

The National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH) has named Case Western Reserve University School of Medicine as the lead institution of an International Center of Excellence for Malaria Research (ICEMR). The $7.9M seven-year grant will accelerate the control of malaria and help eliminate it worldwide.

13 Jul 2010

Wall Street Journal essay examines historical efforts to control malaria

In a Wall Street Journal essay, Sonia Shah, the author of an upcoming book on malaria, outlines the historical efforts to control malaria - from the Roman Empire through today.

13 Jul 2010

Biovest’s publicly-traded shares quoted on newly launched OTCQB Market

Biovest International, Inc., a biotechnology company advancing its personalized cancer vaccine targeting non-Hodgkin's lymphoma, today announced that the Company's publicly-traded shares are now being quoted on the newly launched OTCQB™ Market. The upgraded stock listing is a direct result of Biovest filing its Annual Reports (on Form 10-K) and its Quarterly Reports (on Form 10-Q) with the Securities and Exchange Commission (SEC), as the Company advances plans to emerge from reorganization.

12 Jul 2010

Vaccine News and Research

Latest Vaccine News and Research

Enrollment complete in Nabi's first NicVAX Phase III clinical trial for nicotine addiction

Amorfix grants Biogen Idec exclusive worldwide rights to lead ALS monoclonal antibodies

Hendra virus treatment to be ready in a few months

NIAID awards ATCC multimillion dollar MID-BRR contract

Media outlets focus on audiences towards Alzheimer's disease: Intellect Neurosciences

Health Canada approves FluMist for preventing seasonal influenza

Scientists discover three human antibodies that neutralize HIV

IAS announces recipients of CNIHR grants

New research studies presented at Alzheimer's Association International Conference

Emergent awarded $107M HHS BARDA contract to develop large-scale manufacturing of BioThrax

LSUHSC Professor awarded $2.1M grant to determine role of PCP

Administration to unveil first national HIV/AIDS strategy today

Antigen Express granted patent for AE37 immunotherapeutic vaccine: Generex Biotechnology

Opinions: Haitian rebuilding; Nuclear state vaccine initiatives; HIV rights abuses in China; HIV vaccine

Anti vaccine group has only a week left to heed to HCCC’s warnings

Emergent BioSolutions hosts forum to raise global awareness of the importance of biopreparedness

Clinical trial initiated to evaluate LibiGel on cognitive function in menopausal women

NIAID names Case Western Reserve University as International Center of Excellence for Malaria Research

Wall Street Journal essay examines historical efforts to control malaria

Biovest’s publicly-traded shares quoted on newly launched OTCQB Market

Event guide: 3rd mRNA Process Development & Manufacturing Europe eBook

Redefining control and consistency in anaerobic microbiome workflows

AI in Healthcare: How generative tools are transforming clinical practice

The future of automation: Machine learning–driven hepatocyte and organoid counting

Vaccine News and Research

Latest Vaccine News and Research

Event guide: 3rd mRNA Process Development & Manufacturing Europe eBook

Redefining control and consistency in anaerobic microbiome workflows

AI in Healthcare: How generative tools are transforming clinical practice

The future of automation: Machine learning–driven hepatocyte and organoid counting

Newsletters you may be interested in